X
[{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Treats First Patients in Pivotal JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Receives Eur 1.0 Million to Advance Ongoing JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics\u2019 Allogeneic Cell Therapy Product, Allob, Shows 90% Fusion Rate at 24 Months in Phase II A Studyinn Lumbar Spinal Fusion","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Reaches 50% Treated Patients in Ongoing JTA-004 Phase III Pivotal Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"$14.2 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics, Catalent Ink Pact to Streamline Production of Allogeneic Cell Therapy Product, ALLOB","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Pharma Completes Acquisition of Bone Therapeutics\u2019 Cell Therapy Manufacturing Subsidiary Skeletal Cell Therapy Support","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Completes Recruitment and Patient Treatment in JTA-004 Pivotal Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Treats First Patient in ALLOB Phase IIb Tibial Fracture Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Publishes Results of ALLOB Phase I\/IIa Study for the Treatment of Delayed-Union Fractures in Stem Cell Research & Therapy","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Secures Up to \u20ac16 Million Loan Financing from the European Investment Bank","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Provides Update on the Progress of Clinical Studies","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Implant Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Signs Research Partnership with Implant Therapeutics to Access Induced Pluripotent Stem Cells (iPSC)","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Secures EUR 5 Million Financing","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Signs Definitive Subscription Agreement for A Maximum of EUR 5M Convertible Bonds Facility With ABO","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Optimizes Statistical Analysis and Introduces Interim Analysis in The Ongoing ALLOB Phase IIb Study for High-Risk Tibial Fractures","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Bone Therapeutics to Broaden and Derisk Therapeutic Portfolio by Acquiring Majority Participation in Medsenic","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Pregene","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"$9.7 million","newsHeadline":"Bone Therapeutics to Regain Worldwide Rights to ALLOB","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic SA Provides Update On Its Autoimmune Disease Platform Based On ATO (arsenic trioxide)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics to Start a New Euronext Equity Story with A Change of Name to Bio Senic, Following the Acquisition of A Majority Participation of Medsenic Valued at EUR 40 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Optimizes Statistical Analysis for Its Ongoing ALLOB Phase IIb Study for High-Risk Tibial Fractures, Requiring Fewer Patients and Completes Patient Recruitment","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Delivers a New Post-Hoc Analysis of Its Phase III JTA-004 trial on Knee Osteo-Arthritis with Positive Action on The Most Severely Affected Patient Population","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Bone Therapeutics
Filters
×
FILTER:
Company
Sponsor
Country
Therapeutic Area
Study Phase
Companies By Therapeutic Area
Details:
JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate osteoarthritis pain.
Lead Product(s):
JTA-004
Therapeutic Area: Musculoskeletal
Product Name: JTA-004
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 16, 2023
Details:
ALLOB is an allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. It is being developed for delayed-union fractures and spinal fusion procedures.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery
Product Name: ALLOB
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 23, 2023
Details:
The BioSenic autoimmune platform has been constructed to target systemic autoimmune diseases using arsenic trioxide (Arscimed, ATO). This uses ATO’s first-in-class mechanism of action as an active anti-inflammatory and immunomodulatory agent.
Lead Product(s):
Arsenic Trioxide
Therapeutic Area: Immunology
Product Name: Arscimed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 08, 2022
Details:
The acquisition of Medsenic and its specialized pipeline in the development of optimized formulations of arsenic trioxide (Arscimed) and their applications in serious inflammatory/autoimmune conditions and other potential new indications.
Lead Product(s):
Arsenic Trioxide
Therapeutic Area: Immunology
Product Name: Arscimed
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Medsenic
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
October 25, 2022
Details:
ALLOB (allogeneic bone cell therapy) is an allogeneic osteoblastic cell therapy product derived from ex vivo cultured bone marrow cells. It represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells into bone-forming cells.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery
Product Name: ALLOB
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Pregene
Deal Size: $53.6 million
Upfront Cash: $9.7 million
Deal Type: Termination
October 07, 2022
Details:
Bone Therapeutics would also issue and automatically allot one subscription right to each outstanding share of Bone Therapeutics, in case of statistically positive interim results of the ALLOB Phase IIb trial.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery
Product Name: ALLOB
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Recipient:
Medsenic
Deal Size: $5.0 million
Upfront Cash: $5.0 million
Deal Type: Acquisition
August 10, 2022
Details:
ALLOB (allogeneic bone cell therapy) represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery
Product Name: ALLOB
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 15, 2022
Details:
The proceeds of the financing will contribute to continuing to advance the clinical development of Bone Therapeutics’ lead asset, its allogeneic bone cell therapy, ALLOB.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery
Product Name: ALLOB
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
ABO Securities
Deal Size: $5.4 million
Upfront Cash: Undisclosed
Deal Type: Agreement
May 31, 2022
Details:
The proceeds of the financing will be used to advance the clinical development of Bone Therapeutics’ lead asset, the allogeneic bone cell therapy, ALLOB.
Lead Product(s):
Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery
Product Name: ALLOB
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
ABO Securities
Deal Size: $5.4 million
Upfront Cash: Undisclosed
Deal Type: Financing
April 12, 2022
Details:
The gross proceeds will be used to advance Bone Therapeutics’ lead orthopedic asset, ALLOB, through mid-stage clinical development and will also support the acceleration of the development of the new iMSC cell and gene therapy platform.
Lead Product(s):
Allogeneic Osteoblastic Cells
Therapeutic Area: Musculoskeletal
Product Name: Allob
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $3.7 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
December 03, 2021